A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 104,54 (-52,43%). A mediana é € 113,53 (-48,34%).

Comprar	8
Manter	15
Vender	6

Notícias Ir para o feed de notícias

Moderna faces key day on October 24 over INTerpath-001 data

Moderna and partner Merck & Co will present detailed phase‑3 data on the individualized cancer vaccine Intismeran from the INTerpath‑001 study at the ESMO congress on October 24. According to earlier reports, the primary endpoint of recurrence‑free survival was met; overall survival, the safety profile and the magnitude of the effect remain unknown and are seen as stock catalysts. The share has risen strongly recently, but analysts remain partly cautious; third‑quarter results will also be released on November 6. » Mais em deraktionaer.de
Moderna ahead of key phase 3 data on personalized skin cancer vaccine at ESMO congress

Moderna and Merck will present detailed phase 3 data on Intismeran in combination with Keytruda from the INTerpath‑001 study on October 24 at the ESMO congress. The market expects a substantial reduction in recurrence risk; analysts estimate the hazard ratio for relapse‑free survival at around 0.65. Given a strong price pre‑valuation and a recent nearly 300 percent share gain in a portfolio, the result is seen as decisive for the stock's further valuation. » Mais em deraktionaer.de
Moderna presents details on positive Phase‑3 result for personalized cancer vaccine at ESMO

Moderna achieved positive Phase‑3 results for a personalized cancer vaccine and will present key details at the ESMO annual meeting in Madrid (Oct. 23–27). The report names Moderna as one of three biotech companies with major upside potential following recent breakthroughs in cancer research. Investor note: paid analyses are offered and conflicts of interest are disclosed. » Mais em deraktionaer.de

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2022, Moderna Inc. já distribuiu € 0,17 em dividendos. A última distribuição ocorreu em maio de 2022.

Dados financeiros da empresa

No último trimestre, Moderna Inc. registou receitas de € 127,05 mi e um ganho líquido de -€ 685,2 mi

(EUR)	junho de 2026	YoY
Receitas	127,05 mi	5,46%
Ganho bruto	45,56 mi	133,49%
Ganho líquido	-685,2 mi	2,11%
EBITDA	-616,85 mi	4,33%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 80,82 bi
Número de ações	399,24 mi
Máximo/mínimo de 52 semanas	€ 215,75 - € 19,84
Dividendos	Não
Beta	0,90
PER (PE Ratio)	-28,49
PEG (PEG Ratio)	3,37
P/VC (PB Ratio)	13,31
P/V (PS Ratio)	40,74

Perfil da empresa

Moderna, Inc., ein Biotechnologieunternehmen, entdeckt, entwickelt und vermarktet Boten-RNA-Therapeutika und Impfstoffe zur Behandlung von Infektionskrankheiten, Immunonkologie, seltenen Krankheiten, Herz-Kreislauf-Erkrankungen und Autoimmunerkrankungen in den Vereinigten Staaten, Europa und international. Die Impfstoffe gegen Atemwegserkrankungen umfassen COVID-19, Grippe, Respiratory Syncytial Virus, Endemic HCoV und hMPV+PIV3; die latenten Impfstoffe umfassen Cytomegalovirus, Epstein-Barr-Virus, Humanes Immundefizienz-Virus, Herpes-Simplex-Virus und Varizella-Zoster-Virus; und die Impfstoffe für die öffentliche Gesundheit bestehen aus Zika- und Nipah-Impfstoffen. Das Unternehmen bietet auch systemische sekretorische und Zelloberflächentherapeutika, Krebsimpfstoffe wie personalisierte Krebs-, KRAS- und Checkpoint-Impfstoffe, intratumorale Immuno-Onkologieprodukte, lokalisierte regenerative, systemische intrazelluläre und inhalative pulmonale Therapeutika an. Das Unternehmen unterhält strategische Allianzen mit AstraZeneca PLC, Merck & Co, Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc; Metagenomi, Inc; der Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; und der Bill & Melinda Gates Foundation sowie eine Kooperations- und Lizenzvereinbarung mit Chiesi Farmaceutici S.P.A. Das Unternehmen war früher als Moderna Therapeutics, Inc. bekannt und änderte im August 2018 seinen Namen in Moderna, Inc. Moderna, Inc. wurde im Jahr 2010 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.

Nome	Moderna Inc.
CEO	Stéphane Bancel
Sede	Cambridge, ma EUA
Site	investors.modernatx.com/overview/default.aspx
Setor	Cuidados de saúde
Indústria	Biotecnologia
Entrada em bolsa	07/12/2018
Colaboradores	4.700